Considerations for the Feasibility of Neutralizing Antibodies as a Surrogate Endpoint for COVID-19 Vaccines

To effectively control and prevent the pandemic of coronavirus disease 2019 (COVID-19), suitable vaccines have been researched and developed rapidly. Currently, 31 COVID-19 vaccines have been approved for emergency use or authorized for conditional marketing, with more than 9.3 billion doses of vacc...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jianyang, Mao, Qunying, Wu, Xing, He, Qian, Bian, Lianlian, Bai, Yu, Wang, Zhongfang, Wang, Qian, Zhang, Jialu, Liang, Zhenglun, Xu, Miao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092276/
https://www.ncbi.nlm.nih.gov/pubmed/35572565
http://dx.doi.org/10.3389/fimmu.2022.814365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092276/
https://www.ncbi.nlm.nih.gov/pubmed/35572565
http://dx.doi.org/10.3389/fimmu.2022.814365

Ejemplares similares